RT Journal Article
SR Electronic
T1 Multicentric Evaluation of a Novel Point of Care Electrochemical ELISA Platform for SARS-CoV-2 Specific IgG and IgM Antibody Assay
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.04.21256472
DO 10.1101/2021.05.04.21256472
A1 Kumar, Vinay
A1 Ghosh, Kanad
A1 Chandran, Anagha
A1 Panwar, Sachin
A1 Bhat, Ananthram
A1 Konaje, Shreenivas
A1 Das, Saroj
A1 Srikanta, S
A1 Jaganathan, Latha
A1 Prasad, Sujay
A1 Venkatesh, D B
A1 Shivaram, C.
A1 Krishnaswamy, P R
A1 Bhat, Navakanta
YR 2021
UL http://medrxiv.org/content/early/2021/05/07/2021.05.04.21256472.abstract
AB New diagnostics technologies for the efficient detection and quantification of SARS-CoV-2 Antibodies is very crucial to manage the COVID-19 pandemic, especially in the context of emerging vaccination paradigms. Herein, we report on a novel point-of-care Electrochemical ELISA platform with disposable screen printed electrodes functionalized with SARS-CoV-2 Spike Glycoprotein S1, to enable fast and accurate quantitative estimation of total antibody concentration (IgG and IgM) in clinical samples. The quantification is performed with a comparison of electrochemical redox current against the current produced by the spiked monoclonal antibodies with known concentration. The assay is validated through multicentric evaluation against 3 different FDA authorized Laboratory standard techniques, using both EDTA whole blood and serum samples. We demonstrate that the proposed assay has excellent sensitivity and specificity, making it a suitable candidate for epidemiological surveys and quantification of antibodies in COVID-19 vaccination programs.Competing Interest StatementVinay Kumar and Navakanta Bhat are the co-founders of PathShodh Healthcare Pvt. Ltd., a start-up incubated at the Indian Institute of Science, Bengaluru. They are also the co-inventors on a US patent application 17/228,798, on this technologyFunding StatementWe thank Department of Science and Technology, Government of India for funding this project through CAWACH program; SINE IIT Bombay and IKP Knowledge Park Hyderabad for being the satellite centre for managing the CAWACH program. We also thank Society for Innovation and Development at IISc for seed funding. We are grateful to Department of Biotechnology, Government of India and Biotechnology Industry Research Assistance Council (BIRAC) for their funding support provided for the development of anuPathTM platform.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee by name "Science for Health" with its registered office at No 2, 1A Cross, Marenahalli, J P Nagar 2nd Phase, Bangalore, INDIA-560078, in its meeting held on 18th October 2020, reviewed the study protocols in detail. The committee meeting was attended by 14 members. Based on the detailed documents (Project details and Informed consent forms) submitted, the ethics committee provided approval for this research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data reported in the manuscript is available for verification